ceritinib
Roche ALK Test Gains FDA Approval as CDx for Zykadia
The IHC test was used in clinical studies that led to Zykadia's approval last week as a first-line option for metastatic NSCLC patients with ALK rearrangements.
Novartis' Zykadia Approved for Frontline Treatment of Metastatic, ALK-Positive NSCLC
The expanded indication makes it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.